Extra-articular SpA manifestations | Base model* | Comorbidity model† | Socioeconomic model‡ | Full model§ |
Anterior uveitis, 0–1.5 years of follow-up | 0.57 (0.46–0.70) | 0.58 (0.47–0.72) | 0.61 (0.49–0.77) | 0.62 (0.49–0.78) |
Anterior uveitis, >1.5 years of follow-up | 1.10 (0.83–1.45) | 1.09 (0.82–1.43) | 1.17 (0.87–1.58) | 1.17 (0.87–1.57) |
Psoriasis | 1.35 (1.04–1.76) | 1.28 (0.98–1.67) | 1.36 (0.01–1.82) | 1.31 (0.97–1.76) |
IBD | 0.84 (0.65–1.09) | 0.82 (0.63–1.07) | 0.83 (0.62–1.10) | 0.84 (0.63–1.13) |
*Base model adjusted for baseline characteristics: age, sex, C-reactive protein, peripheral arthritis, Bath Ankylosing Spondylitis Disease Activity Index and type of tumour necrosis factor alpha inhibitorTNFi.
†Comorbidity model adjusted for the same covariates as the base model, and in addition for the presence of each of the chronicconcurrent comorbidities: cardiovascular disease, affective disorders, chronic lung disease, diabetes, chronic kidney diseaseand for a history of a malignancy.
‡Socioeconomic model adjusted for the same covariates as the base model, and in addition for annual household income, sick leave/disability pension rate, level of formal education and country of origin.
§Full model adjusted for all of the above-mentioned covariates.
AS, ankylosing spondylitis; IBD, inflammatory bowel disease; SpA, spondyloarthritis; TNFi, tumour necrosis factor alpha inhibitor.